

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED**

北京同仁堂國藥有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3613)**

**INSIDE INFORMATION  
PROFIT WARNING**

This announcement is made by Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that, based on the preliminary assessment of the Group’s latest unaudited consolidated management accounts and the information currently available to the Board, the revenue of the Group is expected to decrease by 11% to 15% and the profit after tax of the Group is expected to decrease by 18% to 22%, for the year ended 31 December 2023 as compared to the corresponding period in 2022.

The expected decrease in revenue and profit after tax of the Group for the year ended 31 December 2023 is mainly attributable to a deviation between the market actual conditions and demand after the pandemic from expectation, where some distributors in the mainland China were still off-loading the own products of the Group during 2023, which has affected the sales of the Group’s own products in the mainland China. The Company’s management has taken a number of contingency measures instantly, including strengthening distribution channel building and marketing promotion etc., to optimize the marketing environment, thereby enhancing profitability of the Group.

The information contained in this announcement only represents a preliminary assessment based on the financial information currently available to the Board and such information has not been audited or reviewed by the auditors or the audit committee of the Company. The annual results announcement of the Company for the year ended 31 December 2023 is expected to be published on or before 31 March 2024.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Beijing Tong Ren Tang**  
**Chinese Medicine Company Limited**  
**Gu Hai Ou**  
*Chairman*

Hong Kong, 29 January 2024

As at the date of this announcement, the composition of the Board is as follows:

***Executive Directors:***

Mr. Gu Hai Ou (*Chairman*)  
Mr. Yu Jin  
Mr. Chen Fei

***Independent Non-executive Directors:***

Mr. Tsang Yok Sing, Jasper  
Mr. Xu Hong Xi  
Mr. Chan Ngai Chi

***Non-executive Director:***

Ms. Feng Li